LL37 promotes angiogenesis: a potential therapeutic strategy for lower limb ischemic diseases DOI Creative Commons
Yingying Yang, Gang Wu, Yini Wang

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 23, 2025

Purpose To study the angiogenic capacity of antimicrobial peptide LL37 (cathelicidin peptide), explore its molecular mechanisms, and provide new ideas for treating lower limb ischemic diseases. Methods was applied exogenously to human umbilical vein endothelial cells (HUVECs), effects on cell proliferation, migration, angiogenesis were assessed using Cell Counting Kit-8 (CCK-8), plate cloning, scratch, assays. A mouse ischemia model established, with injected intramuscularly days 0, 4, 8. Blood flow recovery evaluated by laser Doppler flowmetry. Immunofluorescence staining detected cluster differentiation 31 (CD31) 34 (CD34) expression, while Hematoxylin Eosin (H&E) muscle morphology. Quantitative real-time polymerase chain reaction (qRT-PCR) Western blotting analyzed gene protein expression changes in HUVECs. Results enhanced proliferative, migratory, pro-angiogenic abilities It significantly improved blood limbs, higher CD31/CD34 more intact qRT-PCR analysis demonstrated elevated angiogenesis-related genes LL37-treated revealed increased vascular growth factor (VEGFA) phosphorylation levels phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target rapamycin (mTOR) pathway cells. Conclusion promotes via VEGFA-PI3K/AKT/mTOR pathway, showing potential improving perfusion.

Язык: Английский

Effect of platelet-rich plasma on angiogenic and regenerative properties in patients with critical limb ischemia DOI Creative Commons
Hamid Tanzadehpanah, Sima Nobari,

A Hoseini

и другие.

Regenerative Therapy, Год журнала: 2025, Номер 28, С. 517 - 526

Опубликована: Фев. 6, 2025

Язык: Английский

Процитировано

1
LL37 promotes angiogenesis: a potential therapeutic strategy for lower limb ischemic diseases DOI Creative Commons
Yingying Yang, Gang Wu, Yini Wang

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Апрель 23, 2025

Purpose To study the angiogenic capacity of antimicrobial peptide LL37 (cathelicidin peptide), explore its molecular mechanisms, and provide new ideas for treating lower limb ischemic diseases. Methods was applied exogenously to human umbilical vein endothelial cells (HUVECs), effects on cell proliferation, migration, angiogenesis were assessed using Cell Counting Kit-8 (CCK-8), plate cloning, scratch, assays. A mouse ischemia model established, with injected intramuscularly days 0, 4, 8. Blood flow recovery evaluated by laser Doppler flowmetry. Immunofluorescence staining detected cluster differentiation 31 (CD31) 34 (CD34) expression, while Hematoxylin Eosin (H&E) muscle morphology. Quantitative real-time polymerase chain reaction (qRT-PCR) Western blotting analyzed gene protein expression changes in HUVECs. Results enhanced proliferative, migratory, pro-angiogenic abilities It significantly improved blood limbs, higher CD31/CD34 more intact qRT-PCR analysis demonstrated elevated angiogenesis-related genes LL37-treated revealed increased vascular growth factor (VEGFA) phosphorylation levels phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target rapamycin (mTOR) pathway cells. Conclusion promotes via VEGFA-PI3K/AKT/mTOR pathway, showing potential improving perfusion.

Язык: Английский

Процитировано

0